Description: There are a variety of regulatory changes that are being contemplated by the National Association of Insurance Commissioners (NAIC) that have the potential to materially impact actuarial, statutory reporting and disclosure requirements relating to reinsurance. This session will provide an introduction to these changes, explaining both the motivation as well as the potential impact these proposed changes may have on US ceding companies. The focus of the presentation will be primarily on changes affecting Asset Adequacy Testing and statutory risk transfer for combination Coinsurance / Yearly Renewable Term agreements. An update will be provided regarding industry responses to proposed changes and the potential timing for implementation of these new requirements.

Description: This session will focus on the topic of Bermuda Reinsurance: Operational Readiness for Changes. The presenters will examine the current state of the reinsurance industry in Bermuda and explore the operational strategies that companies must consider to stay ahead in a rapidly evolving market. The discussion will cover regulatory updates, and market shifts that are influencing the way reinsurance businesses operate. The presenters will also discuss operational capabilities and organizational structure to think about when designing a new entity.

Description: This session will review reinsurance fundamentals, risk assessment techniques, optimization strategies, and regulatory considerations through case studies and best practices. Attendees will gain insights into enhancing capital management, risk mitigation, and improving operating results, utilizing practical insights from both reinsurers and direct experience.

Description: The U.S. life insurance industry has been increasing its exposure to complex assets, either directly as investors or via offshore reinsurance (e.g., Bermuda). In order to address regulatory concerns about such investments and reinsurance arrangements, the NAIC has begun multiple initiatives to improve disclosure and strengthen regulatory requirements, and the Bermuda Monetary Authority is also strengthening its requirements. Hear a summary of these initiatives, and get an update on the latest developments at the NAIC and at the Academy on these topics.

Description: As more gene and cell therapies enter the market at increasingly higher price points, they are ushering in a new era of medicine for rare diseases. Unlike most traditional therapies, gene and cell therapies typically have a short or one-time treatment administration and are anticipated to provide long-term clinical benefits. Actuaries must be prepared to assess, manage, and/or mitigate the risks associated with these therapies. This session includes three different perspectives—a regional plan, a stop loss/reinsurance carrier, and a health care consultant.

Description: This article provides a summary of the revised ASOP 11 ("Treatment of Reinsurance or Similar Risk Transfer Programs Involving Life Insurance, Annuities, or Health Benefit Plans in Financial Reports") which was effective December 1, 2022.

Description: LEARN is an offering to regulators about reinsurance. This article summarizes a session held for Brazilian health regulators in the fall of 2022.

Description: The Best Article in the Reinsurance News 2023 and News from the Reinsurance Section Council

Description: The article “IFRS 17, Economic Volatility, and Reinsurance” (IFRS 17, Economic Volatility, and Reinsurance | SOA) was designated the best article published in Reinsurance News in 2022. It looks at providing industry insights on preparing for the new global accounting standard. The article was submitted by Paul Sauvé (RGA) and it appeared in the June 2022 issue.

Description: The article summarizes the results of the 2024 Life Reinsurance Survey of Individual Life and Group Life business written in the traditional life reinsurance markets of the United States and Canada. The article summarizes the new business volume written in 2024 and 2023 as well as the volume of ceded reinsurance in force at year-end 2024 and 2023.